Uncovering Promising New Therapies for Lung Cancer Patients

In 2020, the American Cancer Society reported the largest single-year drop in cancer deaths ever recorded—a decline attributed mainly to improvements in lung cancer treatment. Listen to leaders from Dana-Farber’s Lowe Center for Thoracic Oncology, Pasi Jänne, MD, PhD, Mark Awad, MD, PhD, David Barbie, MD, Christopher Lathan, MD, MS, MPH, and Julia Rotow, MD, to learn how they are developing treatments that focus on the specific needs of each patient, allowing more patients to live longer, healthier lives. Dana-Farber Trustee Bill Gillen hosted this complimentary educational webinar.

To learn more, visit the Revolutionary Science section of this site.

Give Now

Thank you for your interest in learning more about The Dana-Farber Campaign. You have been added to our email list and will receive updates on ways to join us in defying cancer. You can unsubscribe at any time.

There has been an issue submitting your request. Please try again.

Founded in Boston in 1947, Dana-Farber is a principal teaching affiliate of Harvard Medical School and a federally designated Comprehensive Cancer Center that develops and disseminates innovative patient therapies and scientific discoveries throughout the world. About Our Patient Stories: Dana-Farber shares patient stories which may include descriptions of actual medical results. Dana-Farber provides personalized care for each patient based on their unique needs; their experiences and results will vary.

At Dana-Farber we are committed to an inclusive community where human differences are valued and celebrated, and where all are welcome. We work every day to create an innovative, caring, and inclusive environment where each patient, family, and staff member feels valued and respected.